Purpose / DescriptionThis was a phase 3 single-arm open-label trial to evaluate the safety and efficacy of 8 weeks of glecaprevir-pibrentasvir in 203 adults with genotype 2, 4, 5 or 6 infection without cirrhosis. The majority (71%) had genotype 2 infection; 13% were treatment-experienced, mostly with prior interferon-based therapy. The overall sustained virologic response rate (SVR12) was 96% (189 of 196) by intent-to-treat analysis. Of the 7 patients who did not achieve an SVR12, only 2 were virologic relapses (both genotype 2); the remaining patients were lost to follow-up. Findings from SURVEYOR-II, Part 4 were published in conjunction with ENDURANCE-2 and ENDURANCE-4.